InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (13 ops.)
Insider track record
OtherDisclosed buys
1
Disclosed sells
13
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Gorman Kevin Charles. Officer active across 2 companies, notably Neurocrine Biosciences INC. Cumulatively, 28 disclosures have been logged. Split: 1 buy · 13 sells. Total volume traded: €36.4m. History available since 7 February 2022. The latest transaction was disclosed on 16 June 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Gorman Kevin Charles
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations28 total
10,302 shares0Common StockSEC:0001201096-26-000016:0
205,088 shares@ US$43.240.048% mcap15.4% of flowCommon StockSEC:0001201096-26-000010:0
245,088 shares@ US$154.33180.20% mcap65.5% of flowCommon StockSEC:0001201096-26-000010:1
5,604 shares0Common StockSEC:0001201096-26-000005:0
5,142 shares0Common StockSEC:0001201096-26-000003:0
106,322 shares@ US$35.996.2% of flowCommon StockSEC:0000914475-25-000166:0
13,686 shares0Common StockSEC:0001127602-25-017597:0
9,613 shares@ US$120.37981.9% of flowCommon StockSEC:0000914475-25-000137:0
5,376 shares0Common StockSEC:0000914475-25-000073:0
4,318 shares0Common StockSEC:0000914475-25-000052:0
5,141 shares0Common StockSEC:0000914475-25-000031:0
146,105 shares@ US$32.999.3% of flowCommon StockSEC:0000914475-25-000009:0
2,654 shares@ US$20.6898.1% of flowCommon StockSEC:0001127602-24-024672:0
5,986 shares0Common StockSEC:0001127602-24-018831:0
53 shares@ US$19.121.9% of flowCommon StockSEC:0001127602-24-005195:0
Canonical exit: 13 May 2024 (T+90)
2,832 shares@ US$133.01570.7% of flowCommon StockSEC:0000914475-24-000073:0
2,778 shares@ US$35.990.2% of flowCommon StockSEC:0000914475-24-000056:0
3,040 shares@ US$142.17710.8% of flowCommon StockSEC:0000914475-24-000046:0
2,707 shares@ US$140.68880.7% of flowCommon StockSEC:0000914475-24-000028:0
105,835 shares@ US$19.593.8% of flowCommon StockSEC:0000914475-24-000009:0
9,328 shares@ US$107.39881.8% of flowCommon StockSEC:0001209191-23-047137:0
5,007 shares0Common StockSEC:0001127602-23-019287:0
3,040 shares@ US$105.67720.6% of flowCommon StockSEC:0001209191-23-007912:0
2,707 shares@ US$110.08390.6% of flowCommon StockSEC:0001209191-23-006276:0
2,422 shares@ US$80.82520.0012% mcap50.0% of flowCommon StockSEC:0001209191-22-008211:0
25 of 28 declarations
About Gorman Kevin Charles
GORMAN KEVIN CHARLES is a Director at Neurocrine Biosciences INC and Xencor Inc. He has filed 28 disclosures in total, and across the recent sample of 28 filings, the aggregated amounts are EUR 941 of purchases and EUR 36,423,235 of sales, with filings ranging from 2016-01-13 to 2026-07-08.
